Serum soluble CD44v6 levels in patients with oral and maxillofacial malignancy

  1. SM Chang1,
  2. RD Xing2,
  3. FM Zhang1,
  4. YQ Duan3

Article first published online: 29 JUN 2009

DOI: 10.1111/j.1601-0825.2009.01591.x

Issue

Oral Diseases

Oral Diseases

Volume 15, Issue 8, pages 570–572, November 2009

Additional Information

How to Cite

Chang, S., Xing, R., Zhang, F. and Duan, Y. (2009), Serum soluble CD44v6 levels in patients with oral and maxillofacial malignancy. Oral Diseases, 15: 570–572. doi: 10.1111/j.1601-0825.2009.01591.x

Author Information

  1. 1

    Department of Stomatology, Beijing Friendship Hospital, Capital Medical University, Beijing, China

  2. 2

    Department of Oral and Maxillofacial Surgery, Capital Medical University School of Stomatology, Beijing, China

  3. 3

    Department of Stomatology, The Fourth Hospital Affiliated to Hebei Medical University, Shijiazhuang, China

*Prof. Ru-dong XING, Department of Oral and Maxillofacial Surgery, Capital Medical University School of Stomatology, Beijing 100050 China. Tel: 86-10-67013675, Fax: 86-10-67099045, E-mail: xrdbianjibu@yahoo.com.cn

Publication History

  1. Issue published online: 7 OCT 2009
  2. Article first published online: 29 JUN 2009
  3. Received 5 November 2008; revised 7 May 2009; accepted 26 May 2009

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (215K)

Keywords:

  • CD44v6;
  • oral cancer;
  • serum

Objective:  To determine the levels of serum sCD44v6 in patients with oral cancer and evaluate the value of serum sCD44v6 in adjuvant diagnosis, staging and monitoring treatment response in these patients.

Materials and Methods:  A total of 112 hospitalized patients with oral and maxillofacial malignancy and 28 healthy individuals were examined for serum sCD44v6 levels. Venous blood was collected from these patients and the healthy individuals. One week after treatment, venous blood was collected once again in 60 patients with oral and maxillofacial squamous cell carcinoma (OSCC).

Results:  The sCD44v6 concentration was not significantly different between patients with oral and maxillofacial malignancy and control group (P > 0.05). The levels of serum sCD44v6 in patients with OSCC and salivary carcinoma showed no difference with those in control group (P > 0.05). The sCD44v6 level in patients with stage III and IV disease was higher than that of patients with stage I and II and that of the control group, but the difference was not significant (P > 0.05).  Serum sCD44v6 levels in patients with OSCC after treatment became lower than that prevailed during pretreatment (P < 0.05).

Conclusion:  The possible roles of CD44v6 in the diagnosis of oral and maxillofacial malignancy deserve further elucidation and evaluation. Serum sCD44v6 may be a valuable marker in monitoring treatment response in patients with OSCC.

View Full Article (HTML) Get PDF (215K)